MaxCyte, Inc. Notice of AGM (1589S)
September 28 2017 - 12:15PM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 1589S
MaxCyte, Inc.
28 September 2017
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notification of Annual General Meeting
Maryland, USA - 28 September 2017: MaxCyte (LSE: MXCT, MXCR), a
US-based global company driving the acceleration of the discovery,
development, manufacturing and commercialisation of
next-generation, cell-based medicines, announces that formal notice
and resolutions of the Company's AGM, along with a letter from the
Chairman and the Annual Meeting Proxy Card and Form of Direction,
has been circulated to Shareholders.
These documents are also available in electronic form on the
Company's website: www.maxcyte.com.
The Annual General Meeting of Stockholders is planned to be held
at 11 a.m. GMT on 31 October 2017 at InterContinental London Park
Lane, One Hamilton Place, Park Lane, London W1J 7QY, United
Kingdom.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Duncan Monteith
Ryan McCarthy
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.com
Lindsey Neville
About MaxCyte
MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving
the acceleration of the discovery, development, manufacturing and
commercialization of next-generation, cell-based medicines. The
Company provides its patented, high-performance cell engineering
platform to biopharmaceutical partners engaged in drug discovery
and development, biomanufacturing, and cell therapy, including gene
editing and immuno-oncology. With its robust delivery platform,
MaxCyte's team of scientific experts helps its partners to unlock
their product potential and solve problems. This platform allows
for the engineering of nearly all cell types, including human
primary cells, with any molecule, at any scale. It also provides a
high degree of consistency and minimal cell disturbance, thereby
facilitating rapid, large-scale, clinical and commercial grade cell
engineering in a non-viral system and with low-toxicity concerns.
The Company's cell-engineering platform is FDA-accredited,
providing MaxCyte's customers and partners with an established
regulatory path to commercialize cell-based medicines. MaxCyte is
also developing CARMA, its proprietary, breakthrough platform in
immuno-oncology, to rapidly manufacture CAR therapies for a broad
range of cancer indications, including solid tumours where existing
CAR-T approaches face
significant challenges. For more information, visit http://www.maxcyte.com/.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOABLGDCXBDBGRI
(END) Dow Jones Newswires
September 28, 2017 12:15 ET (16:15 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024